Published in Ann Oncol on February 17, 2013
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med (2017) 4.67
Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience. BMC Cancer (2015) 1.48
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol (2016) 1.12
Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer (2014) 1.08
Systemic therapy for bladder cancer - a medical oncologist's perspective. J Solid Tumors (2014) 0.82
Urothelial carcinoma management in elderly or unfit patients. EJC Suppl (2016) 0.78
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer (2014) 0.78
Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer (2016) 0.78
Urothelial carcinoma: vinflunine offers modest but important survival benefit. Nat Rev Urol (2013) 0.77
Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma. Mol Oncol (2016) 0.76
Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer. Oncotarget (2016) 0.75
A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review. Case Rep Oncol (2015) 0.75
From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples. Front Pharmacol (2016) 0.75
Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. Onco Targets Ther (2017) 0.75
Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience. Ther Adv Urol (2016) 0.75
Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. BMC Cancer (2016) 0.75
Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis. Oncol Lett (2016) 0.75
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet (2005) 3.75
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease. Br J Cancer (2003) 2.47
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol (2004) 2.15
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer (2004) 1.93
The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer (2000) 1.74
Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer (2005) 1.68
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. Eur J Cancer (1993) 1.39
Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol (1996) 1.39
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol (1995) 1.32
Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res (2000) 1.30
Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab (1999) 1.24
Five-year change in statistical designs of phase II trials published in leading cancer journals. Eur J Cancer (2004) 1.24
Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. Cancer (1996) 1.23
The human homologue of the putative proto-oncogene Spi-1: characterization and expression in tumors. Oncogene (1990) 1.21
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol (2001) 1.20
Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab (1999) 1.19
Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) (1986) 1.15
Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol (2010) 1.12
Treatment outcome following radiotherapy in elderly patients with bladder cancer. Radiother Oncol (1997) 1.10
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol (2011) 1.10
Carcinoma in situ of testicular tissue adjacent to malignant germ-cell tumors: a study of 105 cases. Cancer (1981) 1.09
Clinical radiobiology of malignant melanoma. Radiother Oncol (1989) 1.07
Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer (2001) 1.06
Retracted Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol (2006) 1.05
Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol (2006) 1.05
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer (2003) 1.05
Management of extragonadal germ-cell tumors and the significance of bilateral testicular biopsies. Ann Oncol (1992) 1.05
Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol (1998) 1.04
Radiation treatment of carcinoma-in-situ of testis. Lancet (1986) 1.04
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol (2014) 1.03
Adult granulosa-cell tumor of the ovary: a retrospective study of 45 cases. Int J Gynecol Cancer (1997) 1.03
Non-seminomatous testicular germ cell tumours in Denmark 1976-1980. Results of treatment. Acta Radiol Oncol (1984) 1.02
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer (2009) 1.00
Management of carcinoma-in-situ of the testis. Int J Androl (1987) 0.99
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res (1994) 0.99
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer (2007) 0.98
Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer (2010) 0.98
Screening for carcinoma in situ of the contralateral testis in patients with germinal testicular cancer. Br Med J (Clin Res Ed) (1982) 0.98
Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr (2002) 0.96
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer (2004) 0.95
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol (2002) 0.95
Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol (1986) 0.95
Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer (1999) 0.94
Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer. J Urol (2002) 0.94
The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother (1993) 0.93
Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab (1991) 0.93
The growing teratoma syndrome: a woman with nonseminomatous germ cell tumor of the ovary. Gynecol Oncol (1993) 0.93
Sexuality and body image in long-term survivors of testicular cancer. Eur J Cancer (2011) 0.92
Testicular seminoma in Denmark 1976-1980. Results of treatment. Acta Radiol Oncol (1984) 0.91
Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol (2008) 0.90
Carcinoma-in-situ testis in patients with assumed extragonadal germ-cell tumours. Lancet (1987) 0.90
Anticipatory nausea: the role of individual differences related to sensory perception and autonomic reactivity. Ann Behav Med (2007) 0.90
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol (2006) 0.89
Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol (2000) 0.89
Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol (1990) 0.89
Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial. Br J Cancer (2006) 0.89
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. Br J Cancer (2012) 0.88
A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys (1985) 0.88
Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol (2009) 0.87
Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity. Psychother Psychosom (2007) 0.87
Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol (1998) 0.87
Initial management of primary mediastinal seminoma: radiotherapy or cisplatin-based chemotherapy? Eur J Cancer (1998) 0.87
Quantification of melanoma cell-specific MART-1 mRNA in peripheral blood by a calibrated competitive reverse transcription-PCR. Clin Chem (2000) 0.86
Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. Eur J Cancer (2011) 0.86
Epidemiological and clinical aspects of carcinoma in situ of the testis. Eur Urol (1993) 0.86
Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP). Eur J Cancer (2004) 0.86
Oxaliplatin in non-seminomatous germ-cell tumors. Ann Oncol (2004) 0.86
Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res (2000) 0.85
[The French clinical trials ongoing (GETUG and AFU) on urothelial carcinomas, kidney and prostate cancers]. Prog Urol (2010) 0.85
Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer (1994) 0.85
A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma. Acta Oncol (1993) 0.84
Ultrasonically guided 125iodine seed implantation with external radiation in management of localized prostatic carcinoma. Urology (1989) 0.84
[Malignant tumors of the adrenal: contribution to the repository CCAFU INCa]. Prog Urol (2010) 0.84
Interferon gamma regulates a unique set of proteins in fresh human bladder transitional cell carcinomas. Electrophoresis (1999) 0.84
A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Clin Cancer Res (2000) 0.83
Radiotherapy in bladder cancer. Radiother Oncol (1999) 0.83
Non-seminomatous testicular germ cell tumours. Preliminary analysis of ongoing trials in the DATECA Study. Acta Radiol Oncol (1984) 0.83
Orchidectomy alone versus orchidectomy plus radiotherapy in stage I nonseminomatous testicular cancer: a randomized study by the Danish Testicular Carcinoma Study Group. Int J Androl (1987) 0.82
Adult Wilms' tumour: review of 22 cases. Eur J Cancer (1994) 0.82
Current concepts of radiation treatment of carcinoma in situ of the testis. World J Urol (1994) 0.82
Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer. Br J Cancer (2003) 0.82
Interactions of radiation and adriamycin, bleomycin, mitomycin C or cis-diamminedichloroplatinum II in intestinal crypt cells. Br J Cancer (1984) 0.82
Salvage chemotherapy in non-dysgerminomatous germ cell tumours of the ovary. Eur J Cancer (1995) 0.82
Ultrasonically guided insertion of a peritoneo-gastric shunt in patients with malignant ascites. Acta Radiol (1995) 0.82
125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. Br J Cancer (1999) 0.82
[Histological features and principles of treating testicle tumors in the elderly subject]. Prog Urol (2009) 0.81
Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. Cancer Res (1992) 0.81
Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study. Cancer Treat Rep (1986) 0.81
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol (2003) 0.81
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. Br J Cancer (2005) 0.81